TYTakechiyo Yamada

Takechiyo Yamada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takechiyo Yamada has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Characteristics of Hearing Loss Caused by P2RX2 Gene Variants

    by Shogo Oyamada, Shin-Ya Nishio, Takechiyo Yamada, Hiroshi Nakanishi, Kiyoshi Oda, Yohei Honkura, Masaomi Motegi, Taku Ito, Naoko Sakuma, Kozo Kumakawa, et al.

    Background/Objectives: The P2RX2 gene encoding an ATP-gated ion channel purinoreceptor is a genetic cause of autosomal dominant non-syndromic hearing loss (DFNA41). P2RX2 is a rare causative gene and its detailed clinical characteristics remain unclear. Methods: In this study, we performed next-generation DNA sequencing analysis covering 158 genes previously reported to be associated with non-syndromic and syndromic hearing loss in 18,475 patients. Results: We identified 29 patients from 22 independent families carrying candidate P2RX2 variants. All of the patients showed late-onset progressive hearing loss. In addition, several cases showed asymmetric hearing deterioration. Among the 29 patients, 23 from 19 unrelated families carried the same c.1057G>A variant, which was identified as a founder mutation by SNP-based haplotype analysis. Conclusions: Our findings indicate that late-onset asymmetric progressive hearing deterioration is a characteristic/unique feature of P2RX2-associated hearing loss, which may be related to noise exposure. Our results may be useful in further clarifying the natural history of and optimizing the management strategies for P2RX2-related hearing loss.

  • Open Access

    Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

    by Shinsuke Suzuki, Yukie Taguchi, Takuro Kitabayashi, Nobuko Sato, Haruka Kaya, Tomoe Abe, Tentaro Endo, Hitomi Suzuki, Yohei Kawasaki, Takechiyo Yamada

    Background: Nivolumab has been shown to improve the overall survival (OS) of patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, there is a need to identify factors associated with long-term survival (beyond 2 years) in these patients. This study investigated the relationship between pretreatment factors and long-term survival in patients with R/M HNSCC treated with nivolumab. Methods: Forty-nine patients with R/M HNSCC who were treated with nivolumab were retrospectively reviewed. Baseline characteristics, clinical data, and survival outcomes were evaluated. Univariate and multivariate analyses were performed to identify factors associated with long-term survival (OS ≥ 2 years). Results: The median OS in the overall cohort was 11.0 months, and the 2-year survival rate was 34.7%. Long-term survivors (OS ≥ 2 years) had significantly higher proportions of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of 0 or 1, serum albumin levels ≥ 3.5 g/dL, and neutrophil-to-eosinophil ratio (NER) < 32.0 compared to non-long-term survivors. On multivariate analysis, serum albumin levels ≥ 3.5 g/dL, in addition to ECOG-PS score of 0 or 1, were independent predictors of long-term survival. Conclusions: Pretreatment serum albumin levels may be useful for predicting long-term survival in R/M HNSCC patients treated with nivolumab.


  • Open Access

    Intrinsic Oncogenic Function of Intracellular Connexin26 Protein in Head and Neck Squamous Cell Carcinoma Cells

    by Nobuko Iikawa, Yohei Yamamoto, Yohei Kawasaki, Aki Nishijima-Matsunobu, Maya Suzuki, Takechiyo Yamada, Yasufumi Omori

    It has long been known that the gap junction is down-regulated in many tumours. One of the downregulation mechanisms is the translocation of connexin, a gap junction protein, from cell membrane into cytoplasm, nucleus, or Golgi apparatus. Interestingly, as tumours progress and reinforce their malignant phenotype, the amount of aberrantly-localised connexin increases in different malignant tumours including oesophageal squamous cell carcinoma, thus suggesting that such an aberrantly-localised connexin should be oncogenic, although gap junctional connexins are often tumour-suppressive. To define the dual roles of connexin in head and neck squamous cell carcinoma (HNSCC), we introduced the wild-type connexin26 (wtCx26) or the mutant Cx26 (icCx26) gene, the product of which carries the amino acid sequence AKKFF, an endoplasmic reticulum-Golgi retention signal, at the C-terminus and is not sorted to cell membrane, into the human FaDu hypopharyngeal cancer cell line that had severely impaired the expression of connexin during carcinogenesis. wtCx26 protein was trafficked to the cell membrane and formed gap junction, which successfully exerted cell-cell communication. On the other hand, the icCx26 protein was co-localised with a Golgi marker, as revealed by immunofluorescence, and thus was retained on the way to the cell membrane. While the forced expression of wtCx26 suppressed both cell proliferation in vitro and tumorigenicity in mice in vivo, icCx26 significantly enhanced both cell proliferation and tumorigenicity compared with the mock control clones, indicating that an excessive accumulation of connexin protein in intracellular domains should be involved in cancer progression and that restoration of proper subcellular sorting of connexin might be a therapeutic strategy to control HNSCC.